Modus Therapeutics
Stockholm
About Modus Therapeutics
Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $25.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: sto:MODTX
- Website: modustx.com
- Phone: 556669-2199
Industries & Categories
Biotechnology, Clinical Trials, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/modus-therapeutics-89322 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.